SAB Biotherapeutics, Inc. (SABS)

Over the past six months, SAB Biotherapeutics' stock price increased, with a 142.00% increase over the last 12 months. The company closed an $85 million public offering to fund the development of SAB-142 and other activities, following a $175 million private placement. SAB BIO presented clinical data from the Phase 1 trial of SAB-142 at the IDS 2026 conference, reporting C-peptide preservation and improved glycemic control. The company reported full-year 2025 financial results, noting the advancement of SAB-142 into the Phase 2b SAFEGUARD study. SAB Biotherapeutics announced progress on the FDA's phased review of its DiversitAb platform. The company has received a consensus rating of "Moderate Buy" from analysts, with a consensus price target of $10.50.

The demand for SAB Biotherapeutics' products is unlikely to exhibit typical seasonality. Demand will be driven by disease prevalence, clinical efficacy and safety, regulatory approvals, healthcare policies and reimbursement, and the competitive landscape. While infectious diseases can have seasonal peaks, the development and commercialization of treatments involve long-term strategies.

SAB Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing human immunoglobulin G to treat and prevent immune and autoimmune disorders. The company uses its DiversitAb™ platform, which involves genetically engineered transchromosomic bovine to produce fully human polyclonal antibodies. Its lead product candidate, SAB-142, is a fully human anti-thymocyte globulin being developed for autoimmune Type 1 Diabetes. Other product candidates include SAB-185 for COVID-19 and SAB-176 for severe influenza, with pre-clinical candidates like SAB-142 for organ transplant induction/rejection.

SAB Biotherapeutics, Inc. is headquartered in Miami Beach, Florida, with its Research & Development Campus in Sioux Falls, South Dakota. Clinical trial sites for SAB-142 are located in the U.S., Australia, and New Zealand.

SAB Biotherapeutics' brand reputation has been largely positive due to positive Phase 1 clinical data for SAB-142, the advancement of SAB-142 into a Phase 2b study, successful financing rounds, analyst endorsement, and FDA progress on its DiversitAb platform. No significant negative events impacting the company's reputation were found.

SAB Biotherapeutics, Inc. has 49 institutional owners and shareholders holding a total of 36,285,142 shares, representing 7.82% ownership. Major institutional owners include Vivo Capital, LLC, and RA Capital Management, L.P. Individual insiders own 2.69% of the shares, hedge funds hold 6.26%, VC/PE Firms hold 22.5%, and the general public holds 37.1%. Shareholders have experienced substantial dilution in the past year, with total shares outstanding growing by 656.6%.